Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

March 6, 2019

Study Completion Date

April 29, 2019

Conditions
Allergic Rhinitis Due to Tree PollenAllergic ConjunctivitisAllergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

Intra-lymphatic allergenic extract

Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.

BIOLOGICAL

Intra-lymphatic placebo

The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.

Trial Locations (3)

76051

Texan Allergy & Sinus Center, Grapevine

78232

Texan Allergy & Sinus Center, San Antonio

78758

Texan Allergy & Sinus Center, Austin

All Listed Sponsors
lead

Christopher Thompson, MD

OTHER

NCT03682965 - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study | Biotech Hunter | Biotech Hunter